Literature DB >> 15882265

Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice.

Shunya Matsuo1, Jesús M López-Guisa, Xiaohe Cai, Daryl M Okamura, Charles E Alpers, Roger E Bumgarner, Mette A Peters, Guoqiang Zhang, Allison A Eddy.   

Abstract

BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) has been implicated in the pathogenesis of chronic kidney disease based on its up-regulated expression and on the beneficial effects of PAI-1 inhibition or depletion in experimental models. PAI-1 is a multifunctional protein and the mechanisms that account for its profibrotic effects have not been fully elucidated.
METHODS: The present study was designed to investigate PAI-1-dependent fibrogenic pathways by comparing the unilateral ureteral obstruction model (UUO) (days 3, 7, and 14) in PAI-1-overexpressing mice (PAI-1 tg) to wild-type mice, both on a C57BL6 background.
RESULTS: Following UUO, total kidney PAI-1 mRNA and/or protein levels were significantly higher in the PAI-1 tg mice (N= 6 to 8/group) and fibrosis severity was significantly worse (days 3, 7, and 14), measured both as Sirius red-positive interstitial area (e.g., 10 +/- 3.2% vs. 4.5 +/- 1.0%) (day 14) and total kidney collagen (e.g., 11.1 +/- 1.7 vs. 6.2 +/- 1.3 microg/mg) (day 14). By day 14, the expression of two normal tubular proteins, E-cadherin and Ksp-cadherin, were significantly lower in the PAI-1 tg mice (3.2 +/- 0.5% vs. 11.7 +/- 5.9% and 2.6 +/- 1.6) vs. 6.2 +/- 0.8%, respectively), implying more extensive tubular damage. At least four fibrogenic pathways were differentially expressed in the PAI-1 tg mice. First, interstitial macrophage recruitment was more intense (P < 0.05 days 3 and 14). Second, interstitial myofibroblast density was greater (P < 0.05 days 3 and 7) despite similar numbers of proliferating tubulointerstitial cells. Third, transforming growth factor-beta1 (TGF-beta1) and collagen I mRNA were significantly higher. Finally, urokinase activity was significantly lower (P < 0.05 days 7 and 14) despite similar mRNA levels. Gene microarray studies documented that that the deletion of this single profibrotic gene had far-reaching consequences on renal cellular responses to chronic injury.
CONCLUSION: These data provide further evidence that PAI-1 is directly involved in interstitial fibrosis and tubular damage via two primary overlapping mechanisms: early effects on interstitial cell recruitment and late effects associated with decreased urokinase activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882265     DOI: 10.1111/j.1523-1755.2005.00327.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  62 in total

Review 1.  TGF-β1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis.

Authors:  Rohan Samarakoon; Jessica M Overstreet; Stephen P Higgins; Paul J Higgins
Journal:  Cell Tissue Res       Date:  2011-06-04       Impact factor: 5.249

2.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

3.  An in vitro model for the pro-fibrotic effects of retinoids: mechanisms of action.

Authors:  A C Rankin; B M Hendry; J P Corcoran; Q Xu
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 4.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

5.  Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  Sekiko Taneda; Kelly L Hudkins; Anja S Mühlfeld; Jolanta Kowalewska; Jeffrey W Pippin; Stuart J Shankland; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

6.  CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD.

Authors:  Daryl M Okamura; Subramaniam Pennathur; Katie Pasichnyk; Jesús M López-Guisa; Sarah Collins; Maria Febbraio; Jay Heinecke; Allison A Eddy
Journal:  J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 10.121

7.  Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis.

Authors:  Wen-Tan Huang; Hasina Akhter; Chunsun Jiang; Mark MacEwen; Qiang Ding; Veena Antony; Victor John Thannickal; Rui-Ming Liu
Journal:  Exp Gerontol       Date:  2014-11-28       Impact factor: 4.032

8.  Targeted disruption of Cd40 in a genetically hypertensive rat model attenuates renal fibrosis and proteinuria, independent of blood pressure.

Authors:  Steven T Haller; Sivarajan Kumarasamy; David A Folt; Leah M Wuescher; Stanislaw Stepkowski; Manish Karamchandani; Harshal Waghulde; Blair Mell; Muhammad Chaudhry; Kyle Maxwell; Siddhi Upadhyaya; Christopher A Drummond; Jiang Tian; Wanda E Filipiak; Thomas L Saunders; Joseph I Shapiro; Bina Joe; Christopher J Cooper
Journal:  Kidney Int       Date:  2016-09-28       Impact factor: 10.612

Review 9.  Targeting the progression of chronic kidney disease.

Authors:  Marta Ruiz-Ortega; Sandra Rayego-Mateos; Santiago Lamas; Alberto Ortiz; Raul R Rodrigues-Diez
Journal:  Nat Rev Nephrol       Date:  2020-02-14       Impact factor: 28.314

Review 10.  TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities.

Authors:  Rohan Samarakoon; Jessica M Overstreet; Paul J Higgins
Journal:  Cell Signal       Date:  2012-10-11       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.